Adeno-associated viral (AAV) vectors hold great potential for liver-directed gene therapy. Stable and high levels of transgene expression have been achieved in many murine models. Systemic delivery of AAV vectors in nonhuman primates (NHPs) that are natural hosts of AAVs appear to be challenging due to the high prevalence of pre-existing neutralizing antibodies (NAbs). This study evaluates the performance of AAV8, hu.37, and rh.8 vectors expressing green fluorescent protein (GFP) from a liver-specific promoter in rhesus macaques. Two of the animals that received AAV8 showed transduction of 24 and 40% of hepatocytes 7 days after systemic vector delivery. Importantly, expression was detected in several animals after 35 days despite the elevation of liver enzymes and development of transgene-specific T cells in liver. Pre-existing low levels of NAbs profoundly impacted the outcome of gene transfer and redirected vector DNA to spleen. We developed a sensitive in vivo passive transfer assay to detect low levels of NAbs to these novel AAV serotypes. Other strategies need to be developed to reduce immune response to the transgene in order to maintain long-term gene expression.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2839221PMC
http://dx.doi.org/10.1038/mt.2009.245DOI Listing

Publication Analysis

Top Keywords

liver-directed gene
8
gene transfer
8
aav vectors
8
low levels
8
levels nabs
8
pleiotropic effects
4
effects natural
4
aav
4
natural aav
4
aav infections
4

Similar Publications

Adeno-associated virus (AAV) vectors have demonstrated safety and efficacy for gene transfer to hepatocytes in preclinical models, in various clinical trials and from a clinical experience with a growing number of approved gene therapy products. Although the exact duration is unknown, the expression of therapeutic genes in hepatocytes remains stable for several years after a single administration of the vector at clinically relevant doses in adult patients with hemophilia and other inherited metabolic disorders. However, clinical applications, especially for diseases requiring high AAV vector doses by intravenous administrations, have raised several concerns.

View Article and Find Full Text PDF

Gene Therapy for Inherited Liver Disease: To Add or to Edit.

Int J Mol Sci

November 2024

Amsterdam University Medical Center, Tytgat Institute for Liver and Intestinal Research, AG&M, University of Amsterdam, Meibergdreef 69-71, 1105 BK Amsterdam, The Netherlands.

Article Synopsis
  • Patients with severe inherited liver disorders traditionally relied on liver transplants for treatment, which necessitated lifelong immune suppression.
  • Recent advancements in liver-directed gene therapy have made it a viable, less invasive treatment option for conditions like hemophilia A and B, potentially opening doors for treating other recessive liver disorders.
  • Various gene therapy strategies, including gene supplementation, editing, and repair, are being explored in studies, each with its pros and cons depending on the specific liver disease mechanism involved.
View Article and Find Full Text PDF

Recently approved adeno-associated viral (AAV) vectors for liver monogenic diseases haemophilia A and B are exemplifying the success of liver-directed viral gene therapy. In parallel, additional gene therapy strategies are rapidly emerging to overcome some inherent AAV limitations, such as the non-persistence of the episomal transgene in the rapidly growing liver and immune response. Viral integrating vectors such as in vivo lentiviral gene therapy and non-viral vectors such as lipid nanoparticles encapsulating mRNA (LNP-mRNA) are rapidly being developed, currently at the preclinical and clinical stages, respectively.

View Article and Find Full Text PDF
Article Synopsis
  • Hepatocellular carcinoma (HCC) has metabolic abnormalities that help cancer cells grow and resist treatment, making it vital to study new metabolic factors linked to these issues for better understanding and potential therapy advancements.
  • An analysis of cancer data revealed that a particular gene module correlates with advanced HCC disease and the maintenance of cancer stem cells, leading to the identification of 361 deregulated genes, with diacylglycerol kinase eta (DGKH) being a key player in promoting aggressive cancer traits.
  • DGKH's elevated levels in tumors make patients less responsive to treatments, and its action involves enhancing mTOR signaling through phosphatidic acid production; targeting DGKH may improve treatment outcomes
View Article and Find Full Text PDF

Comprehensive genome-wide studies are needed to assess the consequences of adeno-associated virus (AAV) vector-mediated gene editing. We evaluated CRISPR-Cas-mediated on-target and off-target effects and examined the integration of the AAV vectors employed to deliver the CRISPR-Cas components to neonatal mice livers. The guide RNA (gRNA) was specifically designed to target the factor IX gene (F9).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!